Tengli Liu1,2, Peng Sun2, Jiaqi Zou2, Le Wang2, Guanqiao Wang2, Na Liu2, Yaojuan Liu2, Xuejie Ding2, Boya Zhang2, Rui Liang2, Shusen Wang3,4,5, Zhongyang Shen2. 1. Organ Transplant Center, Tianjin First Central Hospital, Nankai University, Building A, Fukang Road 24#, Nankai area, Tianjin City, 300192, China. 2. NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Tianjin, 300384, China. 3. Organ Transplant Center, Tianjin First Central Hospital, Nankai University, Building A, Fukang Road 24#, Nankai area, Tianjin City, 300192, China. shusen@vip.163.com. 4. NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Tianjin, 300384, China. shusen@vip.163.com. 5. Tianjin Key Laboratory for Organ Transplantation, Tianjin First Central Hospital, Tianjin, 300192, China. shusen@vip.163.com.
Abstract
BACKGROUND: NKX6.1 is a transcription factor for insulin, as well as a marker for β cell maturity. Abnormal NKX6.1 expression in β cells, such as translocation from the nucleus to cytoplasm or lost expression, has been shown as a marker for β cell dedifferentiation. METHODS: We obtained pancreatic sections from organ donors and immunofluorescence staining with NKX6.1 and insulin was performed to characterize NKX6.1 expression in subjects with or without type 2 diabetes mellitus (T2DM). RESULTS: Our results showed that cells with insulin expression but no nucleic NKX6.1 expression (NKX6.1Nuc-Ins+), and cells with cytoplasmic NKX6.1 expression but no insulin expression (NKX6.1cytIns-) were significantly increased in T2DM subjects and positively correlated with glycated hemoglobin (HbA1c), indicating the elevated β cell dedifferentiation with NKX6.1 inactivation in T2DM. To investigate whether β cell dedifferentiation has initiated in subjects with higher risks for T2DM, we next analyzed the association between β-cell dedifferentiation level in ND subjects with different ages, body mass index, and HbA1c. The results showed the absolute number and percentage of dedifferentiated β cells with NKX6.1 inactivation did not significantly change in subjects with advanced aging, obesity, or modest hyperglycemia, indicating that the β cell dedifferentiation might mainly occur after T2DM was diagnosed. CONCLUSION: Our results suggested that NKX6.1 expression in β cells was changed in type 2 diabetic subjects, evidenced by significantly increased NKX6.1Nuc-Ins+ and NKX6.1cytIns- cells. This abnormality did not occur more frequently in subjects with a higher risk for T2DM, suggesting that β cell dedifferentiation might be secondary to the pathological changes in T2DM.
BACKGROUND:NKX6.1 is a transcription factor for insulin, as well as a marker for β cell maturity. Abnormal NKX6.1 expression in β cells, such as translocation from the nucleus to cytoplasm or lost expression, has been shown as a marker for β cell dedifferentiation. METHODS: We obtained pancreatic sections from organ donors and immunofluorescence staining with NKX6.1 and insulin was performed to characterize NKX6.1 expression in subjects with or without type 2 diabetes mellitus (T2DM). RESULTS: Our results showed that cells with insulin expression but no nucleic NKX6.1 expression (NKX6.1Nuc-Ins+), and cells with cytoplasmic NKX6.1 expression but no insulin expression (NKX6.1cytIns-) were significantly increased in T2DM subjects and positively correlated with glycated hemoglobin (HbA1c), indicating the elevated β cell dedifferentiation with NKX6.1 inactivation in T2DM. To investigate whether β cell dedifferentiation has initiated in subjects with higher risks for T2DM, we next analyzed the association between β-cell dedifferentiation level in ND subjects with different ages, body mass index, and HbA1c. The results showed the absolute number and percentage of dedifferentiated β cells with NKX6.1 inactivation did not significantly change in subjects with advanced aging, obesity, or modest hyperglycemia, indicating that the β cell dedifferentiation might mainly occur after T2DM was diagnosed. CONCLUSION: Our results suggested that NKX6.1 expression in β cells was changed in type 2 diabetic subjects, evidenced by significantly increased NKX6.1Nuc-Ins+ and NKX6.1cytIns- cells. This abnormality did not occur more frequently in subjects with a higher risk for T2DM, suggesting that β cell dedifferentiation might be secondary to the pathological changes in T2DM.
Authors: Sara Al-Khawaga; Bushra Memon; Alexandra E Butler; Shahrad Taheri; Abdul B Abou-Samra; Essam M Abdelalim Journal: Biol Rev Camb Philos Soc Date: 2017-06-22
Authors: Christian M Cohrs; Julia K Panzer; Denise M Drotar; Stephen J Enos; Nicole Kipke; Chunguang Chen; Robert Bozsak; Eyke Schöniger; Florian Ehehalt; Marius Distler; Ana Brennand; Stefan R Bornstein; Jürgen Weitz; Michele Solimena; Stephan Speier Journal: Cell Rep Date: 2020-04-07 Impact factor: 9.423
Authors: Alexandra E Butler; Sangeeta Dhawan; Jonathan Hoang; Megan Cory; Kylie Zeng; Helga Fritsch; Juris J Meier; Robert A Rizza; Peter C Butler Journal: J Clin Endocrinol Metab Date: 2015-12-23 Impact factor: 5.958
Authors: Ashleigh E Schaffer; Brandon L Taylor; Jacqueline R Benthuysen; Jingxuan Liu; Fabrizio Thorel; Weiping Yuan; Yang Jiao; Klaus H Kaestner; Pedro L Herrera; Mark A Magnuson; Catherine Lee May; Maike Sander Journal: PLoS Genet Date: 2013-01-31 Impact factor: 5.917